- Research article
- Open Access
Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund’s Adjuvant–induced knee arthritis
Arthritis Research & Therapy volume 16, Article number: R64 (2014)
Clinical and preclinical studies have shown that supplementation with ω-3 polyunsaturated fatty acids (ω-3 PUFAs) reduce joint destruction and inflammation present in rheumatoid arthritis (RA). However, the effects of individual ω-3 PUFAs on chronic arthritic pain have not been evaluated to date. Thus, our aim in this study was to examine whether purified docosahexaenoic acid (DHA, an ω-3 PUFA) reduces spontaneous pain-related behavior and knee edema and improves functional outcomes in a mouse model of knee arthritis.
Unilateral arthritis was induced by multiple injections of Complete Freund’s Adjuvant (CFA) into the right knee joints of male ICR adult mice. Mice that received CFA injections were then chronically treated from day 15 until day 25 post–initial CFA injection with oral DHA (10, 30 and 100 mg/kg daily) or intraarticular DHA (25 and 50 μg/joint twice weekly). Spontaneous flinching of the injected extremity (considered as spontaneous pain-related behavior), vertical rearing and horizontal exploratory activity (considered as functional outcomes) and knee edema were assessed. To determine whether an endogenous opioid mechanism was involved in the therapeutic effect of DHA, naloxone (NLX, an opioid receptor antagonist, 3 mg/kg subcutaneously) was administered in arthritic mice chronically treated with DHA (30 mg/kg by mouth) at day 25 post–CFA injection.
The intraarticular CFA injections resulted in increasing spontaneous flinching and knee edema of the ipsilateral extremity as well as worsening functional outcomes as time progressed. Chronic administration of DHA, given either orally or intraarticularly, significantly improved horizontal exploratory activity and reduced flinching behavior and knee edema in a dose-dependent manner. Administration of NLX did not reverse the antinociceptive effect of DHA.
To the best of our knowledge, this report is the first to demonstrate DHA’s antinociceptive and anti-inflammatory effects as individual ω-3 PUFAs following sustained systemic and intraarticular administration in a mouse model of CFA-induced knee arthritis. The results suggest that DHA treatment may offer a new therapeutic approach to alleviate inflammation as well as a beneficial effect on pain-related functional disabilities in RA patients.
Rheumatoid arthritis (RA) is one of the most common forms of chronic inflammatory arthritis and has a significant negative impact on society[1–3]. Joint pain is the most frequent symptom in patients with RA and generally decreases their functional status and quality of life, as it is strongly associated with physical disability, decreased mobility, depression, sleep disturbances and increased health-care costs[4–7]. Current therapies to alleviate joint pain have limited efficacy and/or induce several side effects, given that patients with RA may be exposed to long-term use of these analgesics[8–11]. Therefore, there is a clinical need to develop mechanism-based therapies with better efficacy and fewer side effects than those currently used to treat joint pain in patients with RA.
Clinical reports have shown that intake of ω-3 polyunsaturated fatty acids (ω-3 PUFAs) is associated with a reduction in the severity of RA[12–14]. In the majority of these studies, however, a heterogeneous mixture of the two main active ω-3 PUFAs has been used: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)[15, 16]. Additionally, investigators in several studies have shown that EPA and DHA have remarkably different biological effects. For example, whereas EPA enhances osteoclastogenesis, DHA is a potent inhibitor of osteoclastogenesis[17, 18]. Moreover, DHA, but not EPA, reduces the mouse ear edema induced by phorbol ester. Thus, studies examining the effects of pure ω-3 PUFAs on arthritis pathology and arthritis-induced pain are needed.
Currently, it is believed that spontaneous arthritic pain (that is, joint pain at rest)[20, 21] and movement-evoked pain are driven primarily by a chronic joint inflammation that induces both peripheral and central sensitization. Recently, researchers in preclinical studies have reported that osteoclasts (that is, the cells that resorb bone) play a significant role in arthritis-induced bone loss and contribute to the etiology of arthritic pain[23, 24]. As inflammation and osteoclastogenesis have been shown to be reduced by DHA[17, 18, 25, 26] in different animal models, and because these processes have also been demonstrated to occur in RA[24, 27], we sought to evaluate the effect of chronic administration of pure DHA on knee edema, spontaneous nociception and pain-related functional disabilities in a mouse model of knee arthritis induced by Complete Freund’s Adjuvant (CFA).
Intraarticular delivery has been widely used to administer different drugs to treat symptoms associated with arthritis (for example, pain and inflammation) because this method, as compared to systemic administration, may allow delivery of greater concentrations, increased time that the drug is localized within the joint and fewer side effects[28–31]. Although the effects of DHA have previously been tested in acute pain models after oral, intrathecal[33, 34] and intraplantar[35, 36] injection, no data regarding the efficacy of DHA in arthritic pain models following intraarticular administration have been published to date. Thus, the second major goal of this study was to determine whether sustained intraarticular DHA administration reduces spontaneous pain-related behaviors and knee edema and improves functional outcomes in a mouse model of arthritis of the knee joint.
Experiments were performed on a total of 83 male adult ICR mice (Harlan Laboratories, Mexico City, Mexico) weighing 18 to 25 g at the beginning of the experiments. All animals were housed in our facilities at a constant temperature (22°C to 24°C) and had free access to food and drinking water before the experiments. This study was approved by the Comité de Ética Institucional de la Unidad Académica Multidisciplinaria Reynosa Aztlán de la Universidad Autónoma de Tamaulipas (CEI-UAMRA-2012-10). All experiments were conducted in accordance with the Ethical Guidelines for Investigations of Experimental Pain in Conscious Animals. At the end of the experiments, all animals were killed in a CO2 chamber.
CFA (catalog no. F5881), DHA (catalog no. D2534), olive oil (vehicle; catalog no. W530191) and naloxone (NLX; catalog no. N7758) were purchased from Sigma-Aldrich (Toluca, Mexico). DHA was dissolved in olive oil and administered by oral gavage or intraarticular injection.
Complete Freund’s Adjuvant injection
A version of a previously validated model of arthritic inflammation of the knee joint[38–40] was produced by performing four intraarticular injections of CFA (10 μl) at days 0, 7, 14 and 21 unilaterally into the right knee joint. Briefly, mice were anesthetized using a mixture of ketamine/xylazine (100 mg/kg and 5 mg/kg by intraperitoneal injection, respectively), followed by an intraarticular injection of CFA using a 30-gauge, 0.5-inch needle that was fitted with cannulation tubing such that only 2 to 3 mm of the needle was allowed to puncture the joint. CFA was injected through the patellar ligament into the articular space using the femoral condyles as a guide.
Behavioral measures of arthritic joint pain
Behavioral measures of arthritic joint pain included flinching of the affected limb (spontaneous pain), number of total vertical rearings requiring the use of both hind limbs and horizontal exploratory activity (used as functional outcomes of the affected limb). Briefly, mice were placed in open cylindrical Plexiglas observation chambers (height 30 cm and inside diameter 20 cm) for 20 minutes to allow the mice to acclimate to their surroundings. Mirrors were placed behind the chambers to enable unhindered observation. The number of spontaneous flinches was recorded during a 5-minute observation period as previously described. Flinches were defined as the number of times the animal raised its hind paw, which was used as a measure of spontaneous arthritic pain. Although spontaneous flinching is not present in patients with RA, this behavior may reflect the spontaneous pain that arthritic patients experience without movement (that is, pain at rest) of the affected extremity[21, 41, 42].
The number of total vertical rearings was recorded during a 5-minute observation period while the animals were in the open Plexiglas observation chamber. Total vertical rearings was defined as the number of times the animals stood on both hind limbs while supporting their entire body weight. A reduction in vertical rearing in mice is consistent with the reduction in movement or joint-loading observed in RA patients[21, 42].
Once flinching behavior and vertical rearing had been evaluated, horizontal exploratory activity was quantified using a modified open-field paradigm. Mice were placed in the center of a rectangular acrylic chamber (18 × 27 × 15 cm). The chamber was divided into a grid of equally sized rectangles (nine in total measuring 9 × 6 cm each) using lines drawn on the chamber floor for visual quantification. The total number of times each line was crossed in a 2-minute period was quantified by the experimenter[44, 45].
Chronic oral administration of docosahexaenoic acid
After an acclimatization period of 1 week in our facilities, mice were randomly divided into four groups (n = 7 to 9 per group): one group comprising mice that received oral injections containing CFA and olive oil (vehicle) and three groups comprising mice that received oral injections of CFA and DHA concentrations of 10, 30 or 100 mg/kg. DHA or vehicle was given 2 hours before behavioral analysis on a daily basis from day 15 until day 25 after first CFA injection. Behavioral measures of arthritic joint pain were evaluated at days 0, 11, 18 and 25 after the initial CFA injection. The oral doses of DHA given in this study were similar to those used in a previous study in mice in which the researchers demonstrated a significant reduction in glucose and triglyceride levels. The toxicological profile of DHA demonstrates that this oil is safe in rats (up to a consumption level of 3,290 mg/kg/d) over 90 days of toxicological evaluation[47, 48].
Chronic intraarticular administration of docosahexaenoic acid
To determine the effect of chronic intraarticular administration of DHA, mice were randomly divided into three groups (n = 9 or 10 per group): mice that received intraarticular injections of CFA and olive oil (vehicle) and mice that received intraarticular injections of CFA and DHA (25 and 50 μg/joint). Five microliters of DHA or vehicle were injected into the joint space of the anesthetized animal as described above. DHA was administered at days 15, 19 and 22 after the initial CFA injection. For this protocol, DHA was administered 3 days before behavioral analysis to avoid interference of intraarticular administration of CFA. Behavioral measures of arthritic joint pain were evaluated at days 0, 15, 18 and 25 after the initial CFA injection. At day 15, behavioral measures were performed immediately prior to the intraarticular injection of DHA to prevent any interference with behavioral analysis by the puncture itself. The intraarticular doses of DHA employed were based on those described in previous studies utilizing intrathecal or intraplantar delivery of DHA in acute pain models[33, 36].
To determine whether oral or intraarticular administration of DHA by itself modified behavioral measurements, treatment-naïve mice received oral 30 mg/kg DHA once daily for 10 days or intraarticular 50 μg/joint DHA at days 1, 4 and 7. Next, the number of flinches, vertical rearings and horizontal exploratory activity were evaluated at days 0, 1, 4, 8 and 11 after DHA administration.
Acute oral administration of docosahexaenoic acid
Several studies have shown the effect of DHA in different acute pain models[32, 33]. To determine the acute effect of oral administration of DHA on pain-related behaviors in a mouse model of arthritis, we performed behavioral analysis at 1, 2 and 24 hours after a single oral administration of 30 mg/kg DHA at day 15 after the initial CFA injection. The maximum antinociceptive effects were observed between 30 and 100 mg/kg DHA, so only the 30 mg/kg dose was evaluated further in acute administration studies.
Involvement of opioid mechanism in antinociceptive effect of docosahexaenoic acid
To evaluate the involvement of an endogenous opioid pathway, at day 25 after CFA injection, mice with CFA-induced arthritis were randomly divided into three groups of six animals each: (1) mice that received injections of CFA and olive oil orally (vehicle) as well as subcutaneous injections of 3 mg/kg NLX, (2) mice that received injections of CFA and 30 mg/kg DHA orally as well as 3 mg/kg NLX subcutaneously and (3) mice that received CFA injections and 30 mg/kg DHA orally as well as distilled water subcutaneously (vehicle). DHA was given daily from day 15 until day 25 after the initial CFA injection. At day 25, 90 minutes after DHA administration, NLX or distilled water was subcutaneously administered. Next, behavioral analysis was performed at 30 minutes after NLX administration to ensure that mice were tested within the therapeutic time window of the antagonist[49, 50].
Determination of knee diameter
To quantitatively determine the anti-inflammatory effect of DHA after oral or intraarticular administration, the diameter of the knee joint just below the level of the patella was measured in the anesthetized animal using a digital caliper. In animals that received oral DHA, the knee joint diameter was measured on day 0 (before the initial CFA injection) and on days 14, 18 and 25 after the initial injection of CFA. When DHA was administered intraarticularly, the knee joint diameter was measured on day 0 (before the CFA injection) and on days 15, 18 and 25 after the initial CFA injection.
To determine the effect of a single oral administration of DHA on knee edema in mice with CFA-induced arthritis, the knee diameter was measured at 2 and 24 hours after oral administration of DHA (30 mg/kg) at day 15 after the initial CFA injection. To determine whether intraarticular administration of DHA by itself modified knee joint diameter, knee joints were evaluated in treatment-naïve mice on days 0, 4, 8 and 11 following initial intraarticular DHA administration. The results are expressed as percentage of inflammation compared to that in the contralateral knee joint: Inflammation (%) = [(Ipsilateral knee diameter - Contralateral knee diameter)] ÷ Contralateral knee diameter.
A two-way repeated-measures analysis of variance (ANOVA) followed by Bonferroni post hoc correction was used to compare the behavioral measures between the experimental groups at different time points. The magnitude of the anti-inflammatory effect of DHA was determined using two-way ANOVA followed by the Bonferroni post hoc correction. The statistical significance level was set at P < 0.05. In all possible cases, the investigator responsible for behavioral testing, measuring and counting was blinded to the experimental conditions of each animal.
Effect of chronic oral administration of docosahexaenoic acid on pain-related behaviors
Mice that received only an intraarticular injection of saline or DHA showed minimal spontaneous nociceptive behavior or impairment of functional outcomes (data not shown). In contrast, mice that received CFA injections exhibited a greater number of flinches (considered spontaneous pain-related behavior) than observed in sham-treated mice from day 4 through day 25 after the initial CFA injection (data not shown). Additionally, the number of line crosses in the open field test (pain-related functional disability) and vertical rearings (pain-related functional disability) were significantly reduced in mice that received CFA injections than sham-treated mice as time progressed (data not shown).
To determine the effect of chronic oral administration of DHA on spontaneous nociceptive behavior and on pain-related functional disabilities, DHA was administered daily from day 15 until day 25 after the initial CFA injection (Figure 1A). Mice with CFA-induced arthritis and treated with DHA at three different doses (10, 30 and 100 mg/kg by oral administration) showed significantly fewer flinches than mice with CFA-induced arthritis and treated with vehicle (Figure 1B). The antinociceptive effect of DHA was maintained until day 25. Additionally, chronic oral administration of DHA (at 30 and 100 mg/kg) significantly reversed the CFA-induced impairment of horizontal exploratory activity. This beneficial effect was also maintained until day 25 after the initial CFA injection (Figure 1C). The antinociceptive effect of DHA on these two pain-related behaviors reached a maximum effect between the doses of 30 and 100 mg/kg. DHA administration did not significantly change the CFA-induced reduction in vertical rearing (Figure 1D).
Effect of chronic oral administration of docosahexaenoic acid on knee edema
Repeated injections of CFA significantly increased knee edema in the ipsilateral knee joint as compared to the contralateral knee joint or in the knee joints of mice injected with saline solution (data not shown). In all mice that received CFA injections, knee edema was restricted to the ipsilateral joint with no visual evidence of knee edema in the contralateral hind limb, and this edema was maintained through day 25 after the initial CFA injection. At day 15 after the initial CFA injection, oral administration of DHA or vehicle was initiated and maintained until day 25. The anti-inflammatory effect of chronic oral administration of DHA at doses of 10, 30 and 100 mg/kg was determined at days 18 and 25 after the initial CFA injection (Figure 2A). The diameter of CFA-induced ipsilateral knee edema was reduced by DHA in a dose-dependent manner. This effect was statistically significant at doses of 10, 30 and 100 mg/kg (Figure 2B).
Effect of acute oral administration of docosahexaenoic acid on pain-related behaviors and knee edema
To determine the effect of DHA in the CFA-induced arthritis model following a single administration, we performed behavioral analysis at day 15 after CFA injection. Behavioral analysis revealed that a single oral administration of DHA (30 mg/kg) did not significantly reduce the spontaneous nociceptive behaviors (Figure 3A) or restore the CFA-induced vertical rearing impairment at hours 1, 2 and 24 after DHA administration (Figure 3C). In contrast, acute DHA administration significantly reversed the CFA-induced horizontal exploratory activity impairment (Figure 3B) and reduced the knee edema of the ipsilateral knee joint at 2 and 24 hours as compared to CFA-injected mice treated with vehicle (Figure 3D).
Effect of chronic intraarticular administration of docosahexaenoic acid on pain-related
To determine whether intraarticular administration of DHA would reduce pain-related behaviors and knee edema in the CFA-induce arthritis model, administration of DHA into the knee joint (25 and 50 μg/joint) was performed at days 15, 19 and 22 after initial CFA injection (Figure 4A). Both doses of DHA (25 and 50 μg/joint) decreased spontaneous pain behavior (Figure 4B). The CFA-induced impairment of horizontal exploratory activity was significantly restored by intraarticular DHA administration at both doses on day 25 (Figure 4C). The intraarticular DHA did not significantly change the CFA-induced reduction in vertical rearing (Figure 4D). The anti-inflammatory effect of chronic intraarticular administration of DHA at doses of 25 and 50 μg/joint was determined at days 18 and 25 after the initial CFA injection (Figure 5A). DHA treatment at doses of 25 and 50 μg/joint significantly decreased the diameter of the ipsilateral knee joint on the days evaluated (Figure 5B).
Involvement of opioid mechanism in antinociceptive effect of docosahexaenoic acid
To evaluate a possible mechanism of action for the antinociceptive effect of DHA, we examined the effect of NLX, an opioid receptor antagonist, on DHA antinociceptive action in mice that received CFA injections and were treated with oral DHA. NLX did not reverse the antinociceptive effect of DHA on mice with CFA-induced arthritis (Figure 6). Additionally, NLX by itself did not increase or reduce CFA-induced spontaneous flinches or pain-related functional disabilities (data not shown).
Our present study shows an antinociceptive and anti-inflammatory effect of DHA following repeated systemic or intraarticular treatment in a mouse model of chronic CFA-induced knee arthritis. Although investigators in preclinical studies have reported that DHA has antinociceptive effects, traditional reflex tests of nociception were used in most of these studies (for example, hind paw withdrawal responses to thermal and mechanical stimuli)[32–34, 36], and/or acute pain models have been utilized[32, 33]. In our present study, we utilized a chronic pain model of knee arthritis to evaluate the effect of DHA on long-term measures of spontaneous nociception and pain-related functional deficits, as these measures more closely resemble painful conditions in clinical RA.
Chronic administration of docosahexaenoic acid is more effective than acute administration in reducing pain-related behaviors
Although we observed that acute administration of DHA was able to significantly reduce knee edema and restore CFA-induced horizontal exploratory activity deficits, this treatment did not significantly reduce spontaneous flinching. Although we do not yet know the exact mechanisms underlying this finding, we suggest that CFA-induced arthritic pain might not be driven only by central and peripheral sensitization triggered by chronic inflammation of the knee. In this context, several studies have demonstrated that osteoclast-mediated acidosis and bone loss are also involved in the generation and maintenance of arthritic pain[24, 51, 52]. Researchers in previous studies have shown that treatment with DHA decreases osteoclast activation[17, 18] and that long-term intake of a mixture of ω-PUFAs (containing DHA) reduces urine excretion of markers of bone and cartilage resorption in patients with RA. In light of these findings, we suggest that the greater beneficial effect of chronic DHA as compared to acute DHA on spontaneous pain and functional outcomes may be due to DHA’s ability to reduce arthritis-mediated bone loss and erosion, thereby preserving mechanical bone strength.
Intraarticular administration is as effective as systemic administration at reducing pain and knee edema
Although RA is one of the most common musculoskeletal disorders in the world[1, 4], current therapies used to alleviate joint pain have limited efficacy and/or are associated with significant side effects[9, 11, 54]. For example, owing to the chronic nature of the disease, systemic long-term treatment with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 (COX-2) inhibitors in patients with arthritic pain may induce negative side effects in the cardiovascular and gastrointestinal systems[8–11]. A therapeutic option frequently used to minimize systemic side effects is to deliver the drug directly into the affected joint (for example, by intraarticular administration)[28–31]. Although intraarticular administration has been widely used to deliver corticosteroids and other disease-modifying antirheumatic drugs[55, 56], this method is not frequently used to deliver analgesics in arthritic conditions. In the present study, we evaluated the chronic effect of intraarticular administration of DHA on spontaneous nociception, knee edema and pain-related functional disabilities. Our results show that intraarticular injection of DHA was as effective as oral administration. However, it should be noted that for intraarticular administration, we used doses 80 times lower than the systemic concentration. Given that intraarticular injections may be associated with discomfort, pain and possible risk of infection[31, 57], the number of intraarticular injections should be kept to a minimum. In this study, DHA intraarticular injections were performed twice per week versus on a daily basis for oral administration; however an analgesic and anti-inflammatory effect of DHA was reached. Thus, the results of this study suggest that local delivery of DHA into the affected joints may offer another alternative treatment for arthritic pain and inflammation without the possible development of side effects associated with systemic administration.
Antinociceptive effect of docosahexaenoic acid on arthritic pain does not appear to involve an endogenous opioid mechanism
Investigators in previous studies have demonstrated that pretreatment with NLX prevented the antinociceptive effect of DHA after oral administration in acute pain models including formalin-induced nociception and acetic acid writhing tests in the mouse. Additionally, oral administration of DHA increases plasma levels of β-endorphins in mice. These data, taken together, suggest that DHA exerts an antinociceptive effect via activation of an endogenous opioidergic mechanism. In contrast, our experiments demonstrated that administration of NLX (using a dosage and scheme of administration in mice previously validated by others and in our laboratory)[49, 50] did not reverse the beneficial effect of DHA on CFA-induced flinching and horizontal activity deficit. The reasons for these findings are unclear; however, it is possible that mechanisms underlying DHA antinociception in acute pain models may be different from those involved in chronic pain states and/or there may be a decrease in the levels of endorphins in chronic arthritic conditions. In support of this theory, investigators in a clinical study demonstrated that there is an inverse correlation between serum levels of β-endorphins and rheumatoid disease activity score and the duration of RA.
Possible mechanisms underlying anti-inflammatory and antinociceptive actions of docosahexaenoic acid
Although researchers in several studies have demonstrated anti-inflammatory and antinociceptive effects of DHA following acute administration[32, 34, 36, 60], less is known about the molecular mechanisms underlying these effects. Our possible hypothesis, gleaned from basic scientific literature, is that both direct and indirect effects may explain the biological actions of DHA. First, direct effects may include competition of DHA with arachidonic acid as a substrate for cyclo- and lipoxygenase, thus reducing the production of inflammatory eicosanoids[26, 61, 62]. Moreover, researchers recently demonstrated that the anti-inflammatory actions of DHA may partially be explained by inhibition of lipopolysaccharide-mediated COX-2 induction and activity via direct activation of the free fatty acid receptor 4. However, indirect effects may include the participation of D-resolvins and protectin D1, which are lipid mediators enzymatically synthesized in vivo from DHA and promote the resolution of inflammation with greater potency than their parent precursors[35, 64].
The mechanisms underlying the antinociceptive actions of DHA in arthritic pain conditions remain to be explored. However, the results of a previous study suggest that the anti-inflammatory actions of DHA may also contribute to amelioration of arthritic pain. It also has been shown that DHA may directly modulate the excitability of sensory neurons through inhibition of the voltage-dependent sodium currents in dorsal root ganglion neurons. However, an indirect analgesic effect of DHA on arthritic conditions cannot be ruled out. It was recently shown that DHA affects disease progression in that it reduces knee synovial inflammation, pannus formation, cartilage damage and bone damage as evaluated by histopathological analysis in a collagen-induced arthritis model in the mouse. Both direct actions on sensory neurons and effects on disease progression, in addition to as yet unknown mechanisms, presumably participate in the analgesic actions of DHA in arthritic conditions.
The present study has some limitations. First, we suggest that the beneficial effect of DHA on pain-related functional disabilities may partially be a result of DHA’s inhibiting osteoclast-mediated bone destruction and preserving bone mechanical strength. Whether DHA affects bone mass and microarchitecture in arthritic conditions is unknown. Second, it is possible that intraarticular delivery of olive oil by itself could further increase pain, discomfort and synovial inflammation. However, our results show that treatment-naïve animals that received multiple intraarticular olive oil injections displayed minimal spontaneous flinching and that levels of locomotor activity and vertical rearing were similar in magnitude as those of treatment-naïve mice. The mechanisms driving anti-inflammatory and antinociceptive actions in arthritic conditions by DHA remain to be elucidated. Although our present study suggests that an endogenous opioid pathway does not seem to be involved in the actions of DHA, future studies need to be performed to explore the molecular targets of DHA in painful arthritic conditions.
In our present study, we show that either oral or intraarticular administration of DHA significantly reduced spontaneous flinching behavior and knee edema and improved horizontal exploratory activity in a unilateral CFA-induced knee arthritis model. These results suggest that DHA may be a candidate for further testing as a therapeutic alternative in the treatment of pain-related functional disabilities in patients with RA.
Complete Freund’s adjuvant
- ω-3 PUFA:
Ω-3 polyunsaturated fatty acid.
Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet. 2010, 376: 1094-1108. 10.1016/S0140-6736(10)60826-4.
Firestein GS: Evolving concepts of rheumatoid arthritis. Nature. 2003, 423: 356-361. 10.1038/nature01661.
Symmons DP: Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol. 2002, 16: 707-722. 10.1053/berh.2002.0257.
Woolf AD, Pfleger B: Burden of major musculoskeletal conditions. Bull World Health Organ. 2003, 81: 646-656.
Lubeck DP: The costs of musculoskeletal disease: health needs assessment and health economics. Best Pract Res Clin Rheumatol. 2003, 17: 529-539.
Brooks PM: The burden of musculoskeletal disease—a global perspective. Clin Rheumatol. 2006, 25: 778-781. 10.1007/s10067-006-0240-3.
Cisternas MG, Murphy LB, Yelin EH, Foreman AJ, Pasta DJ, Helmick CG: Trends in medical care expenditures of US adults with arthritis and other rheumatic conditions 1997 to 2005. J Rheumatol. 2009, 36: 2531-2538. 10.3899/jrheum.081068.
van Laar M, Pergolizzi JV, Mellinghoff HU, Merchante IM, Nalamachu S, O’Brien J, Perrot S, Raffa RB: Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J. 2012, 6: 320-330. 10.2174/1874312901206010320.
Tragulpiankit P, Chulavatnatol S, Rerkpattanapipat T, Janwityanujit S, Somjarit S, Sirikhedgon U: Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients. Int J Rheum Dis. 2012, 15: 315-321. 10.1111/j.1756-185X.2012.01716.x.
Ong CK, Lirk P, Tan CH, Seymour RA: An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007, 5: 19-34. 10.3121/cmr.2007.698.
Choy EH, Smith C, Doré CJ, Scott DL: A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford). 2005, 44: 1414-1421. 10.1093/rheumatology/kei031.
Calder PC: Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids. 2006, 75: 197-202. 10.1016/j.plefa.2006.05.012.
Ruggiero C, Lattanzio F, Lauretani F, Gasperini B, Andres-Lacueva C, Cherubini A: Ω-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des. 2009, 15: 4135-4148. 10.2174/138161209789909746.
Miles EA, Calder PC: Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr. 2012, 107: S171-S184. 10.1017/S0007114512001560.
Goldberg RJ, Katz J: A meta-analysis of the analgesic effects of ω-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007, 129: 210-223. 10.1016/j.pain.2007.01.020.
Park Y, Lee A, Shim SC, Lee JH, Choe JY, Ahn H, Choi CB, Sung YK, Bae SC: Effect of ω-3 polyunsaturated fatty acid supplementation in patients with rheumatoid arthritis: a 16-week randomized, double-blind, placebo-controlled, parallel-design multicenter study in Korea. J Nutr Biochem. 2013, 24: 1367-1372. 10.1016/j.jnutbio.2012.11.004.
Yuan J, Akiyama M, Nakahama K, Sato T, Uematsu H, Morita I: The effects of polyunsaturated fatty acids and their metabolites on osteoclastogenesis in vitro. Prostaglandins Other Lipid Mediat. 2010, 92: 85-90. 10.1016/j.prostaglandins.2010.04.001.
Rahman MM, Bhattacharya A, Fernandes G: Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol. 2008, 214: 201-209. 10.1002/jcp.21188.
Raederstorff D, Pantze M, Bachmann H, Moser U: Anti-inflammatory properties of docosahexaenoic and eicosapentaenoic acids in phorbol-ester-induced mouse ear inflammation. Int Arch Allergy Immunol. 1996, 111: 284-290. 10.1159/000237379.
Wagstaff S, Smith OV, Wood PH: Verbal pain descriptors used by patients with arthritis. Ann Rheum Dis. 1985, 44: 262-265. 10.1136/ard.44.4.262.
Papageorgiou AC, Badley EM: The quality of pain in arthritis: the words patients use to describe overall pain and pain in individual joints at rest and on movement. J Rheumatol. 1989, 16: 106-112.
Schaible HG, Ebersberger A, Von Banchet GS: Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002, 966: 343-354. 10.1111/j.1749-6632.2002.tb04234.x.
Bromley M, Woolley DE: Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984, 27: 968-975. 10.1002/art.1780270902.
Nagae M, Hiraga T, Wakabayashi H, Wang L, Iwata K, Yoneda T: Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone. 2006, 39: 1107-1115. 10.1016/j.bone.2006.04.033.
Oliver E, McGillicuddy FC, Harford KA, Reynolds CM, Phillips CM, Ferguson JF, Roche HM: Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC ω-3 PUFA. J Nutr Biochem. 2012, 23: 1192-1200. 10.1016/j.jnutbio.2011.06.014.
Olson MV, Liu YC, Dangi B: Docosahexaenoic acid reduces inflammation and joint destruction in mice with collagen-induced arthritis. Inflamm Res. 2013, 62: 1003-1013. 10.1007/s00011-013-0658-4.
Okamoto K, Takayanagi H: Osteoclasts in arthritis and Th17 cell development. Int Immunopharmacol. 2011, 11: 543-548. 10.1016/j.intimp.2010.11.010.
Allen KD, Adams SB, Setton LA: Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model. Tissue Eng Part B Rev. 2010, 16: 81-92.
Chevalier X: Intraarticular treatments for osteoarthritis: new perspectives. Curr Drug Targets. 2010, 11: 546-560. 10.2174/138945010791011866.
Edwards SH: Intra-articular drug delivery: the challenge to extend drug residence time within the joint. Vet J. 2011, 190: 15-21. 10.1016/j.tvjl.2010.09.019.
Gerwin N, Hops C, Lucke A: Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev. 2006, 58: 226-242. 10.1016/j.addr.2006.01.018.
Nakamoto K, Nishinaka T, Mankura M, Fujita-Hamabe W, Tokuyama S: Antinociceptive effects of docosahexaenoic acid against various pain stimuli in mice. Biol Pharm Bull. 2010, 33: 1070-1072. 10.1248/bpb.33.1070.
Nakamoto K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, Koyama Y, Tokuyama S: Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res. 2012, 1432: 74-83.
Lu Y, Zhao LX, Cao DL, Gao YJ: Spinal injection of docosahexaenoic acid attenuates carrageenan-induced inflammatory pain through inhibition of microglia-mediated neuroinflammation in the spinal cord. Neuroscience. 2013, 241: 22-31.
Park CK, Xu ZZ, Liu T, Lü N, Serhan CN, Ji RR: Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J Neurosci. 2011, 31: 18433-18438. 10.1523/JNEUROSCI.4192-11.2011.
Matta JA, Miyares RL, Ahern GP: TRPV1 is a novel target for ω-3 polyunsaturated fatty acids. J Physiol. 2007, 578: 397-411.
Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983, 16: 109-110. 10.1016/0304-3959(83)90201-4.
Gauldie SD, McQueen DS, Clarke CJ, Chessell IP: A robust model of adjuvant-induced chronic unilateral arthritis in two mouse strains. J Neurosci Methods. 2004, 139: 281-291. 10.1016/j.jneumeth.2004.05.003.
Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Coughlin KA, Kaczmarska MJ, Castaneda-Corral G, Bloom AP, Kuskowski MA, Mantyh PW: Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 2012, 64: 2223-2232. 10.1002/art.34385.
Jimenez-Andrade JM, Mantyh PW: Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Arthritis Res Ther. 2012, 14: R101-10.1186/ar3826.
Jimenez-Andrade JM, Mantyh WG, Bloom AP, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW: The effect of aging on the density of the sensory nerve fiber innervation of bone and acute skeletal pain. Neurobiol Aging. 2012, 33: 921-932. 10.1016/j.neurobiolaging.2010.08.008.
Rojkovich B, Gibson T: Day and night pain measurement in rheumatoid arthritis. Ann Rheum Dis. 1998, 57: 434-436. 10.1136/ard.57.7.434.
Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW: Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6 J mouse femur. J Bone Miner Res. 2007, 22: 1732-1742. 10.1359/jbmr.070711.
Tadaiesky MT, Andreatini R, Vital MABF: Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. Eur J Pharmacol. 2006, 535: 199-207. 10.1016/j.ejphar.2006.02.004.
Rodrigues MRA, Kanazawa LKS, Neves TL M d, da Silva CF, Horst H, Pizzolatti MG, Santos ARS, Baggio CH, de Paula Werner MF: Antinociceptive and anti-inflammatory potential of extract and isolated compounds from the leaves of Salvia officinalis in mice. J Ethnopharmacol. 2012, 139: 519-526. 10.1016/j.jep.2011.11.042.
Shimura T, Miura T, Usami M, Ishihara E, Tanigawa K, Ishida H, Seino Y: Docosahexaenoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM). Biol Pharm Bull. 1997, 20: 507-510. 10.1248/bpb.20.507.
Schmitt D, Tran N, Peach J, Bauter M, Marone P: Toxicologic evaluation of DHA-rich algal oil: genotoxicity, acute and subchronic toxicity in rats. Food Chem Toxicol. 2012, 50: 3567-3576. 10.1016/j.fct.2012.07.054.
Lien EL: Toxicology and safety of DHA. Prostaglandins Leukot Essent Fatty Acids. 2009, 81: 125-132. 10.1016/j.plefa.2009.05.004.
Sevcik MA, Jonas BM, Lindsay TH, Halvorson KG, Ghilardi JR, Kuskowski MA, Mukherjee P, Maggio JE, Mantyh PW: Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer. Gastroenterology. 2006, 131: 900-910. 10.1053/j.gastro.2006.06.021.
Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadée W, Bilsky EJ: In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther. 2005, 313: 1150-1162. 10.1124/jpet.104.082966.
Dieppe PA, Lohmander LS: Pathogenesis and management of pain in osteoarthritis. Lancet. 2005, 365: 965-973. 10.1016/S0140-6736(05)71086-2.
Izumi M, Ikeuchi M, Ji Q, Tani T: Local ASIC3 modulates pain and disease progression in a rat model of osteoarthritis. J Biomed Sci. 2012, 19: 77-10.1186/1423-0127-19-77.
Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G: Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis. Br J Nutr. 2009, 101: 1517-1526. 10.1017/S0007114508076216.
Pisetsky DS, Ward MM: Advances in the treatment of inflammatory arthritis. Best Pract Res Clin Rheumatol. 2012, 26: 251-261. 10.1016/j.berh.2012.03.001.
Hoes JN, Jacobs JWG, Buttgereit F, Bijlsma JWJ: Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol. 2010, 6: 693-702. 10.1038/nrrheum.2010.179.
Konai MS, Vilar Furtado RN, dos Santos MF, Natour J: Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. Clin Exp Rheumatol. 2009, 27: 214-221.
Shemesh S, Heller S, Salai M, Velkes S: Septic arthritis of the knee following intraarticular injections in elderly patients: report of six patients. Isr Med Assoc J. 2011, 13: 757-760.
Nakamoto K, Nishinaka T, Ambo A, Mankura M, Kasuya F, Tokuyama S: Possible involvement of β-endorphin in docosahexaenoic acid-induced antinociception. Eur J Pharmacol. 2011, 666: 100-104. 10.1016/j.ejphar.2011.05.047.
Elbeialy A, Elbarbary M, Kamel M: Peripheral β-endorphin in rheumatoid arthritis: a correlation with the disease activity. Scand J Rheumatol. 1997, 26: 88-91. 10.3109/03009749709115824.
Pineda-Peña EA, Jiménez-Andrade JM, Castañeda-Hernández G, Chávez-Piña AE: Docosahexaenoic acid, an ω-3 polyunsaturated acid protects against indomethacin-induced gastric injury. Eur J Pharmacol. 2012, 697: 139-143. 10.1016/j.ejphar.2012.09.049.
Calder PC: n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006, 83: 1505S-1519S.
Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF: Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest. 1984, 74: 1922-1933. 10.1172/JCI111612.
Li X, Yu Y, Funk CD: Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). FASEB J. 2013, 27: 4987-4997. 10.1096/fj.13-235333.
Serhan CN: Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin. 2006, 24: 341-364. 10.1016/j.atc.2006.01.003.
Hong MP, Kim HI, Shin YK, Lee CS, Park M, Song JH: Effects of free fatty acids on sodium currents in rat dorsal root ganglion neurons. Brain Res. 2004, 1008: 81-91. 10.1016/j.brainres.2004.02.033.
This work was partially supported by a Fondos Mixtos (FOMIX) grant (TAMPS-2011-C35-178650). AMTG, CEMU and PAAV were supported by National Science and Technology Council (CONACYT) fellowships. The authors thank Joseph R Ghilardi for helpful comments on the manuscript.
The authors declare that they have no competing interests.
AMTG designed and executed the experiments and drafted the manuscript. CEMU and PAAV designed and executed the experiments and revised the manuscript. RIAG analyzed and interpreted the data and revised the manuscript. AECP performed data analysis and wrote and critically revised the manuscript. RMMR analyzed and interpreted the data and wrote the manuscript. JMJA conceived of and designed the study, analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
About this article
Cite this article
Torres-Guzman, A.M., Morado-Urbina, C.E., Alvarado-Vazquez, P.A. et al. Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund’s Adjuvant–induced knee arthritis. Arthritis Res Ther 16, R64 (2014). https://doi.org/10.1186/ar4502
- Antinociceptive Effect
- Intraarticular Injection
- Chronic Oral Administration
- Intraarticular Administration
- Vertical Rear